

A Cross-sectional study: The Relationship of Family Support Toward Level Adherence Therapy And Hospitalization In Outpatient Treatment of Schizophrenia

Dwi Aulia Ramdini^{1*}, Melisa Intan Barliana², Nanda Restiana¹, Citra Yuliyanda Pardilawati¹, Ramadhan Triyandi¹, Nurma Suri¹, Yulianasari Pulungan¹

¹ Departement of Pharmacy, Faculty of Medicine, University of Lampung, Lampung, Faculty of Medicine, University of Lampung, Bandar Lampung, Indonesia

² Department of Biological Pharmacy, Biotechnology Pharmacy Laboratory, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, West Java, Indonesia

*Corresponding Author: dwi.aulia@fk.unila.ac.id

ABSTRACT

Adherence is one of the essential components in the management of schizophrenia. However, adherence levels remain suboptimal, ranging from 20-89%. Multiple factors, including sociodemographic characteristics and family support have been reported to influence medication adherence and hospitalization rates. This study aimed to investigate relationship between family support, medication adherence, and hospitalization among patients with schizophrenia at the Mental Health Hospital Lampung Province. A cross-sectional study design was employed, and data were collected through patient interviews. Medication adherence was assessed using the Medication Adherence Rating Scale (MARS), while family support was measured using validated and reliability-tested family support questionnaire. A total of 106 patients met the inclusion criteria, of whom 65% demonstrated high levels of medication adherence. The factor including sex ($p=0,047$), employment status ($p=0,004$), and family support ($p<0.000$) were significantly associated with medication adherence. In addition, age ($p=0.019$), family support ($p<0.001$), and medication adherence ($p<0,000$) were significantly associated with hospitalization. These findings indicate that family support has a positive influence on medication adherence and serves as a protective factor against worsening prognosis, as reflected by reduced hospitalization. This study emphasizes the crucial role of family support in achieving successful treatment outcomes in patients with schizophrenia.

Keywords: Adherence, Family support, Hospitalization, Schizophrenia

INTRODUCTION

Schizophrenia is a chronic and severe mental disorder marked by positive, negative and, cognitive symptoms. This illness requires long-term treatment and it is related with significant deterioration in social functioning (Blackman and MacCabe, 2020). Several positive symptoms are delusion, hallucination, disorganized thinking, disorganized speech and behaviour, while negative symptoms are amotivation, social withdrawal, lack of emotion, anhedonia, and low energy (Kaxhn et al., 2015). The poor adherence remains as global challenges in management of schizophrenia, it contributes nonadherence and also poor outcome. Moreover, this illness could lead the violence behaviour and self harm, this supported by reporting in 1435 experienced self harm in 18 month (Buchanan et al., 2019).

Pharmacology treatment has main role in management of schizophrenia. Adherence is

required to achieve optimal outcomes. However, it often becomes a major problem and challenge in the management of schizophrenia. Nonadherence has many implication, including of uncontrolled psychotic symptoms, symptom exacerbation, rehospitalization, longer length of hospital stay, increased treatment cost, reduce quality of life, and increased morbidity and mortality (Kadakia et al., 2022; Lafeuille et al., 2013; Oates et al., 2020). Adherence refers to the extent to which medication use is appropriate and complies with prescribed treatment. Patient are considered nonadherent when they miss at least 20% of their prescribed medication (Phan, 2016). The prevalence of nonadherence among schizophrenia patient ranged from 20% to 89%, and another study reported that 55% of patient were nonadherent after a first episode psychosis. Moreover, patient with a history nonadherence are

more likely to experience nonadherence in subsequent treatment (Barkhof et al., 2012; Haddad, Brain and Scott, 2014).

Family support is the one of factors contributing in medication adherence and is essential for achieving optimal therapeutic outcomes (Z, Muraraiah and H, 2019). In addition to drug selection, the optimization of supportive environment is an important part of the treatment strategy. Negative stigma in society may make families reluctant to be open to the public. Family support is complex and involves multiple factors, comprising knowledge, socio-economic, and culture. In general there are five psychosocial approached in management of schizophrenia including, cognitive (cognitive behavioral dan cognitive remediation therapy), psychoeducation, family intervention, social-skill training, assertive communication (Chien et al., 2013; Ozsahin et al., 2020).

Several studies have reported that family support is related to patients' medication adherence and hospital admissions (Jessica et al., 2021). A systematic review study reported that family support and health professional play an important role in the treatment of schizophrenia particularly in motivating medication use and reducing adverse effects (Higashi et al., 2013). In Indonesia, stigma toward patients with schizophrenia remains prevalent, including stereotypes, discrimination, and the practice of "pasung" by family (Hartini et al., 2018). Sociodemographics of the community such as low education level, limited awareness of mental health, and low economic status are generally related with negative stigma toward patients with schizophrenia (Hartini et al., 2018). Family support in Indonesia therefore remains challenging to implement. This study aimed to provide an overview of adherence levels and to examine the association between family support and medication adherence among patients receiving mental health services in Lampung Province.

METHODS

This study employed observational study with cross-sectional design. Data were collected using a validated and reliable questionnaire. The study population consisted of patients with schizophrenia attending the outpatient psychiatric clinic of the Provincial Mental Hospital of

Lampung between May and July 2023. Participants were selected using purposive sampling. Ethical approval was granted by the Health Research Ethics Committee of the Faculty of Medicine, University of Lampung (No. 4393/UN26.18/PP.05.02.00/2022). Eligible participants were adults aged 18–60 years with a diagnosis of schizophrenia who were receiving oral antipsychotic therapy, with or without adjunctive medications, were clinically stable, able to communicate effectively, and willing to participate. Patients with refractory schizophrenia, cognitive impairment, or hearing deficits were excluded. Medication adherence was assessed through direct patient interviews, with clinical stability confirmed by the attending psychiatrist. Associations between categorical variables were analyzed using the Chi-square test, with Fisher's exact test applied as an alternative when the assumptions of the Chi-square test were not met.

Adherence Instrument

Medication adherence was measured using the Five Medication Adherence Report Scale (MARS-5). The instrument consists of 10 items assessing medication-taking behavior, attitudes toward medication, and perceived side effects. The questionnaire demonstrated good validity and reliability (Cronbach's $\alpha = 0.725$).

Family Support Instrument

Family support was assessed using a 16-item family support questionnaire developed by Nursalam (2017), measured on a Likert scale (0–3) with both favorable and unfavorable items. Total scores were calculated and converted into percentage values. The instrument demonstrated acceptable validity (two-tailed significance $\leq \alpha 0.05$; $r > 0.254$) and reliability, with a Cronbach's α coefficient of 0.731.

RESULTS

Patients' characteristics

A total of 106 ambulatory patients with schizophrenia fulfilled the inclusion criteria, with their characteristics presented in Table 1. The majority of patients were aged 26–45 years ($n = 68$), and most were male ($n = 73$). Based on educational level, patients were predominantly

educated to the senior high school level, accounting for approximately 50%. In terms of employment status, 61.3% of patients were employed, while the remaining patients were unemployed. Regarding hospitalization history, most patients had been hospitalized, with 41.5% experiencing ≤ 2 hospitalizations and 7.5% experiencing ≥ 3 hospitalizations, whereas 40%

had never been hospitalized. Family support assessment showed that the majority of patients had adequate family support (74.5%), while 25.5% had low family support. The number of medications consumed by patients was <4 in 42% of cases and ≥ 4 in 58% of cases.

Tabel 1. Characteristics of Schizophrenia Patients

Characteristics	Frequency (n=106)	Percentage (%)
Age (year)		
18-25	14	13,2
26-45	68	64,2
46-60	24	22,6
Sex		
Man	73	68,9
Women	33	31,1
Level education		
Primary school	14	13,2
Second school	32	30,2
Tertiary school	53	50
University	7	6,6
Status pekerjaan		
Employee	65	61,3
Unemployee	41	38,7
Hospitalizations		
Never	54	40,9
≤ 2 times	44	41,5
≥ 3 times	8	7,5
Family support		
High	79	74,5
Low	27	25,5
Number of medication (mean)		
< 4	44	42
≥ 4	62	58

MARS Measurement

The dominant responses were related to patients' perceptions of their treatment, with 94.3% of patients reporting a clear understanding of their medication. A total of 61% of patients reported having experienced forgetting to take their medication, and 72.2% reported discontinuing therapy when they perceived improvement. Uncomfortable experiences such as fatigue and lethargy were reported by 58.9% of patients, while 50.9% reported feeling "like a

zombie" after taking medication. Overall, 65% of patients demonstrated high adherence, whereas 35% showed low adherence.

Table 2. Frequencies of Responses on the MARS among outpatients schizophrenia

No	Questions	Yes	No
A1	Do you ever forget to take your medication? Yes/No	61 (57,5)	45 (42,5)
A2	Are you careless at times at taking medication? Yes/No	51 (48,1)	55 (51,9)
A3	When you feel better, do you sometimes stop taking your medication? Yes/No	77 (72,6)	29 (27,4)
A4	Sometimes if you feel worse when you take the medication, do you stop taking it? Yes/No	92 (86,8)	14 (13,2)
A5	I take my medication only when I am sick. Yes/No	70 (66,0)	36 (34,0)
A6	It is unnatural for my mind and body to be controlled by medication. Yes/No	62 (58,5)	44 (41,5)
A7	My thoughts are clearer on medication. Yes/No	100 (94,3)	6 (5,7)
A8	By staying on medication, I can prevent getting sick. Yes/No	95 (89,6)	11 (10,4)
A9	I feel weird, like a 'zombie', on medication. Yes/No	54 (50,9)	52 (49,1)
A10	Medication makes me feel tired and sluggish. Yes/No	62 (58,5)	45 (41,5)

Family support Measurement

As shown in Table 3, family support among patients with schizophrenia was assessed across four domains: emotional, informational, instrumental, and appraisal support. Emotional support demonstrated the highest mean score (84.02%). Most patients reported receiving acceptance and attention from their families, with

46.2% indicating that family members always accompanied them when they felt anxious or needed support, 42.5% reporting that families consistently motivated medication intake and regular follow-up, and 51.9% stating that families continued to pay attention to their condition during illness.

Tabel 3. Distribution of Responses to the Family Support Questionnaire Among Patients with Schizophrenia

No.	Family support	Always	Often	Sometimes	Never
Emotional Aspect					
P1	The family does not differentiate between the patient and other family members	1 (0,9)	1 (0,9)	6 (5,7)	98 (92,5)
P2	The family is willing to accompany the patient when they are anxious or need a friend	49 (46,2)	24 (22,6)	17 (16,0)	16 (15,1)
P3	The family motivates the patient to take medication and have regular control	45 (42,5)	36 (34,0)	18 (17,0)	7 (6,6)
P4	The family continues to pay attention to the patient's condition during illness	55 (51,9)	28 (26,4)	20 (18,9)	3 (2,8)
Total score (mean)					356 (84,02%)
Information aspect					
P5	The family reminds the patient to take medication regularly	51 (48,1)	17 (16,0)	13 (12,3)	25 (23,6)
P6	The family helps provide appropriate information about the patient's illness	15 (15,2)	26 (24,5)	19 (17,9)	35 (33,0)
P7	The family explains the instructions regarding the medication given to the patient	44 (41,5)	18 (17,0)	9 (8,5)	35 (33,0)

P8	The family helps direct the patient's abilities so that they are more useful and become achievements	43 (40,6)	27 (25,5)	25 (23,6)	11 (10,4)
Total Score (mean)				286 (67,45%)	
Instrumental aspect					
P9	The family provides time to accompany the patient for treatment at the hospital	70 (66,0)	15 (14,2)	10 (9,4)	11 (10,4)
10	The family facilitates the transportation needed by the patient to get to the hospital	79 (74,5)	19 (17,9)	5 (4,7)	3 (2,8)
P 11	While at home, the family accompanies the patient to take the medicine, until the medicine is actually taken	35 (33,0)	17 (16,0)	9 (8,5)	45 (42,5)
12	The family provides time to communicate with the patient while at home	14 (13,2)	56 (52,8)	29 (27,4)	7 (6,6)
Total score (means)				321 (75,77%)	
Appraisal aspect					
13	The family gives praise to the patient when the patient does activities at home	16 (15,1)	39 (36,8)	22 (20,8)	29 (27,4)
14	The family gives the patient a sense of trust when they are facing problems	27 (25,5)	41 (38,7)	23 (21,7)	15 (14,2)
15	The family helps increase the patient's self-esteem and self-confidence during treatment	34 (32,1)	46 (43,4)	8 (7,5)	18 (17,0)
Total score (means)				285 (67,14%)	

Informational support showed a moderate mean score (67.45%). Nearly half of the patients reported that their families always reminded them to take medication regularly (48.1%). However, lower proportions were observed for the provision of illness-related information and explanation of medication instructions, with 33.0% of patients reporting that families never provided information about the illness and never explained medication instructions.

Instrumental support demonstrated a relatively high mean score (75.77%). Most patients reported that their families always facilitated transportation to the hospital (74.5%) and accompanied them during treatment visits

DISCUSSION

This study showed that the majority of patients with schizophrenia had a high level of medication adherence (65%); however, a proportion of patients still demonstrated low adherence, which may increase the risk of

(66.0%). In contrast, supervision of medication intake at home was less consistent, with 42.5% of patients reporting that family members never accompanied them until the medication was actually taken.

Appraisal support showed the lowest mean score among the four domains (67.14%). A total of 27.4% of patients reported never receiving praise for their activities at home, while 14.2% reported not receiving a sense of trust from family members when facing problems. Additionally, 17.0% of patients indicated that their families did not support efforts to improve self-esteem and self-confidence during treatment.

treatment failure and relapse. Nonadherence among patients with schizophrenia is a global issue and has been consistently reported in various studies, including systematic reviews and meta-analyses that reported wide ranges of adherence

rates (Ljungdalh, 2017; Loots et al., 2021). Nonadherence not only affects poor clinical outcomes but is also associated with an increased risk of rehospitalization, longer duration of hospital stay, and the emergence of dangerous behaviors, including violence and self-harm (Barliana et al., 2023; Buchanan et al., 2019). The frequency of rehospitalization or hospitalization rate is one of the outcomes commonly measured to evaluate the effectiveness of an intervention. Hospitalization is often used as an outcome indicator because it is frequently related to medication nonadherence; therefore, it is commonly selected to assess prognosis in schizophrenia (Barliana et al., 2023; Dilokthornsakul et al., 2016; Egglefield et al., 2020). The assessment of family support as perceived by patients in this study showed variation across different domains.

Emotional and instrumental support were found at higher levels than informational and appraisal support domains. This pattern indicates that families play an active role in providing emotional and practical assistance, such as supervising medication intake and fulfilling patients' daily needs. Emotional support is a particularly important aspect in strengthening psychological resilience when patients face their illness in both personal and social contexts (Akgenç & Ünsal, 2025). These findings differ from a study conducted in Ciamis, West Java, which reported that most socially isolated patients with schizophrenia experienced low levels of emotional support (Nurherliyany et al., 2020). This difference suggests the presence of contextual and cultural variations in family support patterns. Conversely, the informational and appraisal domains in this study were categorized at lower levels. Both domains are closely related to family understanding of the illness and treatment, as well as the family's ability to provide psychological reinforcement and positive feedback to patients. Limited informational support may contribute to poor patient insight into the illness and its treatment, which has been recognized as one of the key determinants of medication nonadherence (Kulkarni & Reeve-Parker, 2015).

Family knowledge and involvement in illness-related education play an important role in improving adherence among patients with schizophrenia (Nuralita & Khairunisa, 2022).

Therefore, these findings indicate areas that still require family-based interventions.

Family support is essential in the management of severe psychiatric disorders. The active role of the family as a source of support is highly needed by patients to ensure optimal care, particularly when patients are at home. This study emphasizes three key aspects of family support: (1) supervision of medication intake, (2) provision of continuous and optimal care, and (3) empowerment of patients with schizophrenia. Family support also contributes to improving relationships between patients and their families (Purba et al., 2020). In contrast, evidence shows adverse outcomes when families restrain or confine patients. A qualitative study conducted by Novy Helena et al. (2018) reported that the practice of pasung may negatively affect the adaptive functioning of patients with schizophrenia. Patients with schizophrenia after experiencing pasung require strong family support to improve their social functioning. Family support, such as a positive family atmosphere or living with loved ones, may help improve medication adherence during the early phase of treatment (Zhang & Ye, 2020). Furthermore, previous studies have demonstrated a relationship between knowledge about schizophrenia, informational support, appraisal or esteem support, instrumental support, emotional support, and medication adherence (Mamang et al., 2024).

This study demonstrated a significant association between family support and medication adherence among patients with schizophrenia. Patients who received higher levels of family support showed higher adherence, whereas those with lower family support were more likely to be nonadherent. Statistical analysis indicated a significant relationship between the two variables ($p = 0.000$). These findings are consistent with previous studies reporting that family support is an important predictor of medication adherence in patients with schizophrenia (Purba et al., 2020). Family support contributes through several mechanisms, including supervision of medication intake, enhancement of patient motivation, reduction of self-stigma, and increased feelings of safety and emotional attachment within the family environment.

In addition to family support, other factors such as gender and employment status were also found to be associated with medication adherence. Higher adherence among female patients compared with male patients is consistent with findings from previous studies (Barliana et al., 2023), which have linked this difference to behavioral factors, social roles, and responses to treatment. Employment status was also positively correlated with adherence, as adherent patients tended to have more stable clinical conditions, enabling them to resume social functioning, including employment. Employment status has also been associated with health-related quality of life among patients with schizophrenia (Bouwman et al., 2015). Employment and income may support patient independence and enhance self-esteem, which can contribute positively to symptom improvement and recovery (Khalid et al., 2023).

Self-stigma and public stigma remain major challenges for patients with schizophrenia in reintegrating into society. A qualitative study by Khalid et al. (2023) highlighted these challenges in the implementation of employment-support programs for clinically stable psychiatric patients. Medication adherence plays a crucial role in improving both positive and negative symptoms, which subsequently leads to better social functioning and quality of life (Martini et al., 2018; Stentzel et al., 2018).

Cultural factors and community beliefs also influence medication adherence. Studies in developing countries have shown that the use of alternative treatments, limited illness insight, and beliefs in supernatural causes of mental illness remain major barriers to adherence (Subu et al., 2022). These findings highlight the importance of culturally sensitive psychoeducation, particularly approaches that actively involve families as key partners in the care of patients with schizophrenia. These findings have important clinical implications. Family-based interventions should focus not only on emotional and instrumental support but also on strengthening informational and appraisal support through structured psychoeducation programs. Such approaches may improve family understanding of the illness, reduce stigma, and enhance the family's capacity to support medication adherence. In addition, social reintegration of clinically stable patients,

including employment support, may improve self-esteem and quality of life, thereby supporting long-term recovery.

Family interventions have been shown to improve treatment outcomes and are widely implemented in schizophrenia care. These interventions aim to promote a positive family environment, reduce expressed emotion, and increase family knowledge regarding early signs and symptoms of relapse (Okpokoro et al., 2014). Family support encompasses four domains: emotional, informational, instrumental, and appraisal support.

Positive outcomes have also been reported from the caregiving experience itself. A qualitative study by Darban et al. (2021) identified positive effects among families caring for patients with schizophrenia, including strengthened family bonds, enhanced life insight, and improved social mobility. These findings suggest that caregiving experiences may provide meaningful benefits to families, and such experiences may be shared by clinicians with families of newly diagnosed patients.

Cultural factors and community beliefs also influence medication adherence. Studies in developing countries have shown that the use of alternative treatments, limited illness insight, and beliefs in supernatural causes of mental illness remain major barriers to adherence (Subu et al., 2022). These findings highlight the importance of culturally sensitive psychoeducation, particularly approaches that actively involve families as key partners in the care of patients with schizophrenia.

These findings have important clinical implications. Family-based interventions should focus not only on emotional and instrumental support but also on strengthening informational and appraisal support through structured psychoeducation programs. Such approaches may improve family understanding of the illness, reduce stigma, and enhance the family's capacity to support medication adherence. In addition, social reintegration of clinically stable patients, including employment support, may improve self-esteem and quality of life, thereby supporting long-term recovery.

Family interventions have been shown to improve treatment outcomes and are widely implemented in schizophrenia care. These interventions aim to promote a positive family

environment, reduce expressed emotion, and increase family knowledge regarding early signs and symptoms of relapse (Okpokoro et al., 2014). Family support encompasses four domains: emotional, informational, instrumental, and appraisal support. Positive outcomes have also been reported from the caregiving experience itself. A qualitative study by Darban et al. (2021) identified positive effects among families caring for patients with schizophrenia, including strengthened family bonds, enhanced life insight, and improved social mobility. These findings suggest that caregiving experiences may provide meaningful benefits to families, and such experiences may be shared by clinicians with families of newly diagnosed patients.

ACKNOWLEDGEMENTS

We would like to express our sincere gratitude to all individuals who have contributed to the completion of this manuscript. Special

REFERENCES

- Akgeç, F., & Ünsal, G. (2025). Family support from the perspectives of individuals with schizophrenia: A qualitative study. *Journal of Psychiatric Nursing*, 16(2). <https://doi.org/10.14744/phd.2025.70471>
- Barkhof, E., Meijer, C. J., de Sonnevile, L. M. J., Linszen, D. H., & de Haan, L. (2012). Interventions to improve adherence to antipsychotic medication in patients with schizophrenia-A review of the past decade. *European Psychiatry*, 27(1), 9–18. <https://doi.org/10.1016/j.eurpsy.2011.02.005>
- Barliana, M. I., Ramdini, D. A., Afifah, N. N., Alfian, S. D., & Sumiwi, S. A. (2023). Investigating the Effect of Adherence to Antipsychotic Therapy on the Length of Stay and Number of Hospitalizations in Patients with Schizophrenia – A Descriptive Analysis. *Patient Preference and Adherence*, 17, 2737–2747. <https://doi.org/10.2147/PPA.S430083>
- Blackman, G., & MacCabe, J. H. (2020). Schizophrenia. In *Medicine (United Kingdom)* (Vol. 48, Issue 11). <https://doi.org/10.1016/j.mpmed.2020.08.004>
- Bouwman, C., De Sonnevile, C., Mulder, C. L., & Hakkaart-van Roijen, L. (2015). Employment and the associated impact on quality of life in people diagnosed with schizophrenia. *Neuropsychiatric Disease and Treatment*, 11. <https://doi.org/10.2147/NDT.S83546>
- Buchanan, A., Sint, K., Swanson, J., & Rosenheck, R. (2019). Correlates of future violence in people being treated for schizophrenia. *American Journal of Psychiatry*, 176(9). <https://doi.org/10.1176/appi.ajp.2019.18080909>
- Chien, W. T., Leung, S. F., Yeung, F. K. K., & Wong, W. K. (2013). Current approaches to treatments for schizophrenia spectrum disorders, part II: psychosocial interventions and patient-focused perspectives in psychiatric care. *Neuropsychiatric Disease and Treatment*, 9, 1463. <https://doi.org/10.2147/NDT.S49263>
- thanks to the Faculty of Medicine, University of Lampung, for providing research grant funding that supported this study.

CONCLUSION

In conclusion, this study demonstrates that sociodemographic factors, including gender, employment status, and family support, are associated with medication adherence among patients with schizophrenia. Age, family support, and adherence were also found to contribute to hospitalization rates. Patients with better adherence tended to receive stronger family support. These findings emphasize the importance of strengthening family support through collaboration with healthcare professionals, including pharmacists, to enhance patient and family knowledge and improve treatment adherence.

- Darban, F., Mehdipour- Rabori, R., Farokhzadian, J., Nouhi, E., & Sabzevari, S. (2021). Family achievements in struggling with schizophrenia: life experiences in a qualitative content analysis study in Iran. *BMC Psychiatry*, 21(1). <https://doi.org/10.1186/s12888-020-03025-w>
- Dilokthornsakul, P., Thoopputra, T., Patanaprteep, O., Kongsakon, R., & Chaiyakunapruk, N. (2016). Effects of medication adherence on hospitalizations and healthcare costs in patients with schizophrenia in Thailand. *SAGE Open Medicine*, 4. <https://doi.org/10.1177/2050312116637026>
- Egglefield, K., Cogan, L., Leckman-Westin, E., & Finnerty, M. (2020). Antipsychotic medication adherence and diabetes-related hospitalizations among Medicaid recipients with diabetes and schizophrenia. *Psychiatric Services*, 71(3). <https://doi.org/10.1176/appi.ps.201800505>
- Haddad, P. M., Brain, C., & Scott, J. (2014). Nonadherence With Antipsychotic Medication. *Dovepress*, 43–62.
- Hartini, N., Fardana, N. A., Ariana, A. D., & Wardana, N. D. (2018). Stigma toward people with mental health problems in Indonesia. *Psychology Research and Behavior Management*, 11, 535. <https://doi.org/10.2147/PRBM.S175251>
- Higashi, K., Medic, G., Littlewood, K. J., Diez, T., Granström, O., & de Hert, M. (2013). Medication adherence in schizophrenia: Factors influencing adherence and consequences of nonadherence, a systematic literature review. *Therapeutic Advances in Psychopharmacology*, 3(4). <https://doi.org/10.1177/2045125312474019>
- Jessica, L., Fithriyah, I., & Ardani, I. G. A. I. (2021). The Importance of Family Support in Successful Treatment Adherence of Schizophrenic Patient. *Jurnal Psikiatri Surabaya*, 10(2). <https://doi.org/10.20473/jps.v10i2.26453>
- Kadakia, A., Catillon, M., Fan, Q., Williams, G. R., Marden, J. R., Anderson, A., Kirson, N., & Dembek, C. (2022). The Economic Burden of Schizophrenia in the United States. *The Journal of Clinical Psychiatry*, 83(6), 43278. <https://doi.org/10.4088/JCP.22M14458>
- Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., Van Os, J., & Insel, T. R. (2015). Schizophrenia. *Nature Reviews Disease Primers*, 1(November). <https://doi.org/10.1038/nrdp.2015.67>
- Khalid, K., Jamaluddin, R., & Ismail, M. S. (2023). Enhancing employment outcome among stable psychiatric patients: Lesson learnt on innovative model of work inclusion. *BMJ Open Quality*, 12(2). <https://doi.org/10.1136/bmjoq-2022-002139>
- Kulkarni, J., & Reeve-Parker, K. (2015). Psychiatrists' awareness of partial and non-adherence to antipsychotic medication in schizophrenia: Results from the Australian ADHES survey. *Australasian Psychiatry*, 23(3). <https://doi.org/10.1177/1039856215576396>
- Lafeuille, M. H., Laliberté-Auger, F., Lefebvre, P., Frois, C., Fastenau, J., & Duh, M. S. (2013). Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: A retrospective database analysis. *BMC Psychiatry*, 13. <https://doi.org/10.1186/1471-244X-13-221>
- Ljungdahl, P. M. (2017). Non-adherence to pharmacological treatment in schizophrenia and schizophrenia spectrum disorders – An updated systematic literature review. In *European Journal of Psychiatry* (Vol. 31, Issue 4). <https://doi.org/10.1016/j.ejpsy.2017.08.001>

- Loots, E., Goossens, E., Vanwesemael, T., Morrens, M., Van Rompaey, B., & Dilles, T. (2021). Interventions to improve medication adherence in patients with schizophrenia or bipolar disorders: A systematic review and meta-analysis. In *International Journal of Environmental Research and Public Health* (Vol. 18, Issue 19). <https://doi.org/10.3390/ijerph181910213>
- Mamang, A., Anwar, S., & Nurhayati, N. (2024). Analysis of the Relationship between Knowledge About Schizophrenia and Family Support on Medication Adherence Among Those Undergoing Repeated Treatment at Dr. Soeharto Heerdjan Mental Hospital: Analisis Hubungan antara Pengetahuan Tentang Skizofrenia dan Dukungan Keluarga terhadap Kepatuhan Minum Obat pada Pasien yang Menjalani Perawatan Berulang di Rumah Sakit Jiwa Dr. Soeharto Heerdjan. *Jurnal Ilmiah Ilmu Keperawatan Indonesia*, 14(02), 22–31. <https://doi.org/10.33221/JIIKI.V14I02.3357>
- Martini, L. C., Barbosa Neto, J. B., Petreche, B., Fonseca, A. O., Dos Santos, F. V., Magalhães, L., Marques, A. G., Soares, C., Cordeiro, Q., Attux, C., & Bressan, R. A. (2018). Schizophrenia and work: Aspects related to job acquisition in a follow-up study. *Revista Brasileira de Psiquiatria*, 40(1). <https://doi.org/10.1590/1516-4446-2016-2128>
- Morken, G., Widen, J. H., & Grawe, R. W. (2008). Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. *BMC Psychiatry*, 8. <https://doi.org/10.1186/1471-244X-8-32>
- Novy Helena, R., Daulima, C., & Yulia Wardani, I. (2018). The experience of people with mental disorders in social function adaptation after suffering from pasung. *Enfermeria Clinica*, 28. [https://doi.org/10.1016/S1130-8621\(18\)30169-4](https://doi.org/10.1016/S1130-8621(18)30169-4)
- Nuralita, N., & Khairunisa, D. (2022). Relationship between Family Knowledge and Compliance in Medication for Schizophrenia Outpatient at Prof. M. Ildrem Mental Hospital. *Open Access Macedonian Journal of Medical Sciences*, 10(T7), 130–133. <https://doi.org/10.3889/OAMJMS.2022.9280>
- Nurherliyany, M., Rahmana, S. T., & Rosmiati, R. (2020). Overview Of Family Emotional And Instrumental Support Of Schizophrenic Patients With Social Isolation. *JURNAL VNUS (Vocational Nursing Sciences)*, 2(1). <https://doi.org/10.52221/jvnus.v2i1.144>
- Oates, G. R., Juarez, L. D., Hansen, B., Kiefe, C. I., & Shikany, J. M. (2020). Social risk factors for medication nonadherence: Findings from the CARDIA study. *American Journal of Health Behavior*, 44(2), 232–243. <https://doi.org/10.5993/AJHB.44.2.10>
- Okpokoro, U., Adams, C. E., & Sampson, S. (2014). Family intervention (brief) for schizophrenia. In *Cochrane Database of Systematic Reviews* (Vol. 2014, Issue 3). <https://doi.org/10.1002/14651858.CD009802.pub2>
- Ozsahin, I., Abebe, S. T., & Mok, G. S. P. (2020). A multi-criteria decision-making approach for schizophrenia treatment techniques. *Archives of Psychiatry and Psychotherapy*, 22(2). <https://doi.org/10.12740/APP/111624>
- Phan, S. V. (2016). Medication adherence in patients with schizophrenia. *International Journal of Psychiatry in Medicine*, 51(2), 211–219. <https://doi.org/10.1177/0091217416636601>
- Purba, J. M., Simamora, R. H., Karota, E., & Siregar, C. T. (2020). Family support for persons with schizophrenia after physical restraint and confinement. *Enfermeria Clinica*, 30, 53–56. <https://doi.org/10.1016/J.ENFCLI.2019.12.026>
- Stentzel, U., van den Berg, N., Schulze, L. N., Schwaneberg, T., Radicke, F., Langosch, J. M., Freyberger, H. J., Hoffmann, W., & Grabe, H. J. (2018). Predictors of medication

- adherence among patients with severe psychiatric disorders: Findings from the baseline assessment of a randomized controlled trial (Tecla). *BMC Psychiatry*, 18(1). <https://doi.org/10.1186/s12888-018-1737-4>
- Subu, M. A., Holmes, D., Arumugam, A., Al-Yateem, N., Maria Dias, J., Rahman, S. A., Waluyo, I., Ahmed, F. R., & Abraham, M. S. (2022). Traditional, religious, and cultural perspectives on mental illness: a qualitative study on causal beliefs and treatment use. *International Journal of Qualitative Studies on Health and Well-Being*, 17(1). <https://doi.org/10.1080/17482631.2022.2123090>
- Thompson, K., Kulkarni, J., & Sergejew, A. A. (2000). Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. *Schizophrenia Research*, 42(3), 241–247. [https://doi.org/10.1016/S0920-9964\(99\)00130-9](https://doi.org/10.1016/S0920-9964(99)00130-9)
- Z, N., Muraraiah, S., & H, C. (2019). Medication adherence in schizophrenia: Understanding patient's views. *National Journal of Physiology, Pharmacy and Pharmacology*, 9(0), 1. <https://doi.org/10.5455/njppp.2019.9.0206002032019>
- Zhang, J., & Ye, C. (2020). Factors associated with loss to follow-up of outpatients with depression in general hospitals. *Journal of International Medical Research*, 48(5). <https://doi.org/10.1177/0300060520925595>